Barclays raised the firm’s price target on Catalent to $63 from $47 and keeps an Equal Weight rating on the shares ahead of the Q2 report. The analyst says the company’s intra-quarter commentary has lowered expectations for a bioprocessing destocking recovery, biotech funding has stalled and capex spending is bouncing along the bottom due to constrained pharma budgets. The firm continues to favor contract research organizations on valuation, and bioprocessing names “as it is still the only market that is improving.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTLT:
- Early notable gainers among liquid option names on June 21st
- Catalent’s Strategic Merger and Executive Compensation Plans
- Catalent stockholders approve transaction with Novo Holdings
- Catalent downgraded to Sell from Buy at Argus
- Catalent’s Merger Deal with Novo Holdings: A Tightrope Walk Amidst Restrictive Clauses and Hefty Termination Fees
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue